Moderna reports initial mRNA-2808 T-cell engager results in multiple myeloma
Company / institutional announcement · Moderna / ACCESS Newswire
Source published: · Event / reporting date: 2026-11-04
Site published: 2026-11-05 · Updated: 2026-11-05
This source is linked automatically. Choose a question to get started.
What changed
Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.
Why it may matter
Analysis: The results offer early human evidence for multiplexed mRNA protein production; durability, dose optimization, and safety require further evaluation.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections